Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanistic Study of Indigo Naturalis in Psoriasis
NCT02088281Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2012
- Primary completion
- Jul 2013
- Countries
- 1
- Sponsor
- Chang Gung Memorial Hospital
- Modality
- HM (Herbal Medicine)
- Drugs
- lindioil
- Conditions
- Psoriasis vulgaris (PV)
01
Overview
Phase 2, open-label, single-arm trial of lindioil in Psoriasis vulgaris (PV), sponsored by Chang Gung Memorial Hospital. Primary endpoint: The change of psoriasis severity compared to the change of Th1/ Th17 related cytokines from the peripheral blood at 8 weeks. Started Nov 2012; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Indigo naturalis ointment
Topical application of Indigo naturalis extract in oil ointment
03
Endpoints
Primary
The change of psoriasis severity compared to the change of Th1/ Th17 related cytokines from the peripheral blood
Secondary
The relationship of the change in psoriasis severity and the associated change of the concentration of indirubin from the peripheral blood
The relationship of the change in psoriasis severity and the associated change in the Th1/ Th17 related cytokines from the target psoriatic lesion
Beyond the preview
Go deeper on NCT02088281.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02088281.